EMEA-001877-PIP01-15-M02 - paediatric investigation plan
fremanezumab
PIPHuman
Teva GmbH
Tel. +41 552201546
E-mail: info-era-clinical@teva.de
P/0411/2019: EMA decision of 4 December 2019 on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (AJOVY), (EMEA-001877-PIP01-15-M02)